Locoregional Recurrence after Mastectomy: Incidence and Outcomes

Buchanan, Claire; Dorn, Paige L.; Fey, Jane; Giron, Gianpiero; Naik, Arpana; Mendez, Jane; Murphy, Colleen; Sclafani, Lisa M.

doi:10.1016/j.jamcollsurg.2006.06.015

Cited by 127 publications

(72 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, these results should be confirmed by direct comparison in much larger series. The LR and cancer-related death rates were not significantly different in the two groups and compared favorably with the findings of other published series of patients who underwent SSM and patients with locally advanced disease who were treated by mastectomy with or without reconstruction [5,54,55]. The recurrence rates reported in the literature increased with stage, from 3% for stage I to 11.1% for stage III, from 3.7% for T1 to 9.9% for T2-T4, and from 0% for stage I to 25% for stage III [9,11,13].…”

Section: Discussionsupporting

confidence: 78%

“…We conclude that our surgical procedure is a safe option, and after these preliminary results we found no difference in comparison with standard approaches using delayed breast reconstruction. However, our study findings would be strengthened by a longer followup, as LR rates and cancer-related death are known to increase over time [20,55,59,60].…”

Section: Discussionmentioning

confidence: 85%

See 1 more Smart Citation

New concept for immediate breast reconstruction for invasive cancers: feasibility, oncological safety and esthetic outcome of post-neoadjuvant therapy immediate breast reconstruction versus delayed breast reconstruction: a prospective pilot study

Giacalone

Rathat

Daurès

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Feasibility and oncological safety of postadjuvant skin-sparing mastectomy (SSM) plus immediate breast reconstruction (IBR) cannot be evaluated by randomized trials. However, comparative study could modify guidelines for the oncosurgical treatment of invasive breast cancer. Our study compared the feasibility, oncological safety and esthetic outcome of SSM plus latissimus dorsi (LD) flap IBR after chemotherapy (CT) and radiotherapy (RT) with the standard management for invasive breast cancer: mastectomy as primary treatment, adjuvant CT and RT, and LD flap delayed breast reconstruction (DBR). Twenty-six selected patients with stages IIA-IIIA breast cancer were offered post-neoadjuvant SSM plus IBR with LD flap plus implant (IBR group). Seventy-eight other patients had primary mastectomy, adjuvant CT and RT, and LD-assisted DBR (DBR group). After 4.1 years (range 1-8) of follow-up, feasibility, oncological safety, and esthetic outcome were compared. Sixteen (61%) early complications were reported for the IBR group versus 44 (56%) for the DBR group (P = 0.645). Early implant loss was 0% in IBR versus 12% in DBR. IBR had 8 (30%) late complications versus 17 (21%) for DBR (P = 0.362). Capsular contracture and reconstruction failure rates were similar. Local recurrence was 7.7% (2/26) in IBR and 6.4% (5/78) in DBR (P = 0.823). Cosmetic evaluation by independent physicians and by the patients themselves was identical in the two groups. Our concept provides a basis for offering more women the opportunity to elect for immediate reconstruction, even in the setting of radiation therapy.

show abstract

Section: Discussionsupporting

confidence: 78%

Section: Discussionmentioning

confidence: 85%

New concept for immediate breast reconstruction for invasive cancers: feasibility, oncological safety and esthetic outcome of post-neoadjuvant therapy immediate breast reconstruction versus delayed breast reconstruction: a prospective pilot study

Giacalone

Rathat

Daurès

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Local recurrence rates after mastectomy ranges from 5% to 15% at 10 years after treatment with a median time of appearance of just 2-3 years (even later, in case of systemic therapy administration) (1,5,26). Approximately 80% to 90% of local recurrences appear within 5 years after mastectomy and nearly all in the first 10 years.…”

Section: Breast Local Recurrencementioning

confidence: 99%

Management of Breast Cancer Locoregional Recurrence

Voinea¹,

Sandru²,

Blidaru³

2017

chr

View full text Add to dashboard Cite

RezumatRecidiva în cancerul mamar reprezintã o provocare pentru clinician din cauza tratamentului nestandardizat şi necesitã de obicei o abordare multidisciplinarã. Aceasta este cheia pentru un control bun al bolii pe termen lung şi pentru un tratament cu intenţie curativã. Recidiva localã în cancerul mamar poate apãrea dupã tratamentul chirurgical conservator sau dupã mastectomie iar recidiva regionalã implicã limfonodulii ipsilaterali axilari, mamari interni sau supraclaviculari. Prognosticul recidivei locale dupã tratamentul chirurgical conservator pare sã fie mai bun decât dupã mastectomie în termenii apariţiei metastazelor la distanţã şi a supravieţuirii globale. De asemenea, prognosticul recidivei axilare este mai bun decât cel al recidivei supraclaviculare sau mamare interne. Recidiva locoregionalã în cancerul mamar reprezintã mai degrabã un marker al apariţiei metastazelor decât un factor determinant al acestora. Opţiunile terapeutice pentru recidiva loco-regionalã în cancerul de sân impun decizii multidisciplinare şi din acest motiv este foarte importantã comisia oncologicã multidisciplinarã. Fiecare pacient trebuie sa primeascã cel mai bun tratament oncologic personalizat. Review Article a multidisciplinary approach. This is the key for a good long term disease control and for a management with curative intent. The local recurrence in breast cancer appears after breast conserving treatment (BCT) or after mastectomy, and the regional recurrence involves the ipsilateral axillary, internal mammary or supraclavicular lymph nodes. Local recurrence prognosis after BCT seems to be better than after mastectomy regarding distant metastases occurrence and overall survival. Prognosis of axillary recurrence is better than prognosis of supraclavicular and internal mammary recurrence. Locoregional recurrence in breast cancer represents rather a marker for the appearance of distant metastases than a determinant factor for them. Management options for locoregional recurrence of cancer require multidisciplinary input decision making and for this reason the multidisciplinary tumor-board (MTD) is very important. Each patient should receive the best individualized oncologic treatment.

show abstract

“…Predominantly, local recurrence was the first site of disease, and the majority of patients were and stayed free of distant recurrence. Furthermore, a recent meta-analysis underlined the importance of follow-up visits demonstrating that 47% of local recurrences after mastectomy were detected at routine visits when patients were asymptomatic [22]. So far, it is not known if an early diagnosis of locoregional recurrence will extend survival due to lead time and length time bias.…”

Section: Role Of Baseline Staging and Follow-upmentioning

confidence: 99%

Diagnosis, Staging and Follow-up in Breast Cancer Patients*

Stickeler¹

2007

Breast Care

View full text Add to dashboard Cite

The role of imaging in the diagnosis and local staging of breast cancer is an important issue. Current guidelines recommend mammography for diagnosis of breast cancer, and ultrasound is often used as an additional imaging option. The usage of magnetic resonance imaging (MRI) is a controversial issue. The rationale for initial staging in breast cancer patients is the identification of gross evidence of metastatic disease that would influence further treatment strategies. However, so far, early detection of metastatic disease has had no relevant impact on patient survival. Follow-up examinations can help to detect early recurrences which are potentially curable but might impair quality of life. Disseminated tumor cells (DTCs) are an independent prognostic marker in breast cancer and a potential new staging tool. Detection of DTCs in bone marrow offers a wide spectrum of applications reaching from individual risk assessment to characterization of target antigen expression with consequent appropriate treatment choice. This review describes and discusses new aspects of these topics presented at the 10^th St. Gallen International Conference on ‘Primary therapy of early breast cancer’ 2007.

show abstract

Locoregional Recurrence after Mastectomy: Incidence and Outcomes

Cited by 127 publications

References 17 publications

New concept for immediate breast reconstruction for invasive cancers: feasibility, oncological safety and esthetic outcome of post-neoadjuvant therapy immediate breast reconstruction versus delayed breast reconstruction: a prospective pilot study

New concept for immediate breast reconstruction for invasive cancers: feasibility, oncological safety and esthetic outcome of post-neoadjuvant therapy immediate breast reconstruction versus delayed breast reconstruction: a prospective pilot study

Management of Breast Cancer Locoregional Recurrence

Diagnosis, Staging and Follow-up in Breast Cancer Patients*

Contact Info

Product

Resources

About